• About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
Menu
  • About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
MPOX
JOIN
Posted on May 31, 2023September 20, 2023

BC Case Definition: Neonatal Encephalopathy (Korean Translation)

This post contains the Korean translation of the Brighton Collaboration case definition for neonatal encephalopathy, to be utilize...
Read More
Posted on May 9, 2023September 20, 2023

BC Case Definition: Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM) (Korean Translation)

This post contains the Korean translation of the Brighton Collaboration case definition for Encephalitis, myelitis, and acute diss...
Read More
Posted on May 2, 2023September 21, 2023

Korean translations of BC case definition publications are now available

Korean translations of the BC case definition publications have now been developed by the COVID-19 Vaccine Safety Research Cente...
Read More
Posted on May 2, 2023September 20, 2023

BC Case Definition: Guillain Barré and Miller Fisher Syndromes (Korean Translation)

This post contains the Korean translation of the Brighton Collaboration case definition for Guillain Barré and Miller Fisher Synd...
Read More
Posted on May 2, 2023September 20, 2023

BC Case Definition: Kawasaki Disease (Korean Translation)

This post contains the Korean translation of the Brighton Collaboration case definition for Kawasaki Disease, to be utilized in th...
Read More

Recent Posts

  • Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa feverJune 2, 2025
  • Strengthening Vaccine Safety from Outbreaks to Infants: SPEAC at the World Vaccine CongressMay 27, 2025
  • Brighton Collaboration News — May 2025May 19, 2025
  • Safety by Numbers – February 2025February 19, 2025
  • Brighton Collaboration News — Sept 2024September 9, 2024

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

  • Case Definitions
  • Safety Templates
  • Covid-19
  • Trusted Sources
Linkedin

© Brighton Collaboration  2023. All rights reserved.

  • Disclaimer and Privacy Policy